
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by former FDA staffers Eva Temkin, partner at Arnold & Porter, and Elizabeth Trentacost, senior associate at Arnold & Porter. They reflect on 2026 regulatory developments and discuss the implications and nuances of Operation TrialBlazer.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
More episodes from "Better Biopharma"



Don't miss an episode of “Better Biopharma” and subscribe to it in the GetPodcast app.








